How have JSPRW shares performed in 2024?

Jasper Therapeutics' stock was trading at $0.08 at the beginning of 2024. Since then, JSPRW shares have increased by 143.8% and is now trading at $0.1950. View the best growth stocks for 2024 here .

Are investors shorting Jasper Therapeutics?

Jasper Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,800 shares, a decrease of 19.1% from the April 30th total of 4,700 shares. Based on an average trading volume of 21,900 shares, the short-interest ratio is currently 0.2 days. View Jasper Therapeutics' Short Interest .

How do I buy shares of Jasper Therapeutics?

Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:JSPRW

Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free JSPRW Stock Alerts

$0.20

-0.01 (-4.88%)

(As of 05/31/2024 ET)

Compare

Today's Range: $0.18
▼
$0.20
50-Day Range: $0.12
▼
$0.23
52-Week Range: $0.04
▼
$0.38

Volume: 1,809 shs
Average Volume: 27,453 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Trends

Get Jasper Therapeutics alerts:

Ad Porter & Company

Kiss of death from Joe Biden

I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.

I have uncovered a bombshell that changes everything… and threatens everything.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

JSPRW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JSPRW Stock News Headlines

March 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Ayr Wellness (OtherAYRWF) and Jasper Therapeutics (JSPR)

March 9, 2023 | markets.businessinsider.com

Jasper Therapeutics (JSPR) Receives a Buy from Credit Suisse

See More Headlines

Receive JSPRW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:JSPRW
CUSIP: N/A
CIK: 1788028
Web: N/A
Phone: 650-549-1400
Fax: N/A
Employees: 45
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Ronald A. Martell (Age 62)
President, CEO & Director
Comp: $892.45k
Mr. Herbert C. Cross (Age 52)
CFO & Corporate Secretary
Dr. Luca Di Noto Ph.D.
Senior Vice President of Technical Operations
Mr. David Ku M.D.
Vice President of Corporate Development, Portfolio Strategy & Management
Mr. Matthew Ford
Vice President of Human Resources
Dr. Wendy Pang M.D.
Ph.D., Senior Vice President of Research & Translational Medicine
Dr. Edwin Jonathan Tucker M.D. (Age 52)
Chief Medical Officer
Ms. Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

JSPRW Stock Analysis - Frequently Asked Questions

How have JSPRW shares performed in 2024?: Jasper Therapeutics' stock was trading at $0.08 at the beginning of 2024. Since then, JSPRW shares have increased by 143.8% and is now trading at $0.1950.
View the best growth stocks for 2024 here.
Are investors shorting Jasper Therapeutics?: Jasper Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,800 shares, a decrease of 19.1% from the April 30th total of 4,700 shares. Based on an average trading volume of 21,900 shares, the short-interest ratio is currently 0.2 days.
View Jasper Therapeutics' Short Interest.
How do I buy shares of Jasper Therapeutics?: Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JSPRW) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial